243 related articles for article (PubMed ID: 22321214)
41. Discovery of a potent, selective, and orally active phosphodiesterase 10A inhibitor for the potential treatment of schizophrenia.
Bartolomé-Nebreda JM; Delgado F; Martín-Martín ML; Martínez-Viturro CM; Pastor J; Tong HM; Iturrino L; Macdonald GJ; Sanderson W; Megens A; Langlois X; Somers M; Vanhoof G; Conde-Ceide S
J Med Chem; 2014 May; 57(10):4196-212. PubMed ID: 24758746
[TBL] [Abstract][Full Text] [Related]
42. Phosphodiesterase 10A inhibitors: a 2009 - 2012 patent update.
Kehler J
Expert Opin Ther Pat; 2013 Jan; 23(1):31-45. PubMed ID: 23210904
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and preliminary biological evaluation of potent and selective 2-(3-alkoxy-1-azetidinyl) quinolines as novel PDE10A inhibitors with improved solubility.
Rzasa RM; Frohn MJ; Andrews KL; Chmait S; Chen N; Clarine JG; Davis C; Eastwood HA; Horne DB; Hu E; Jones AD; Kaller MR; Kunz RK; Miller S; Monenschein H; Nguyen T; Pickrell AJ; Porter A; Reichelt A; Zhao X; Treanor JJS; Allen JR
Bioorg Med Chem; 2014 Dec; 22(23):6570-6585. PubMed ID: 25456383
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.
Siuciak JA; Chapin DS; Harms JF; Lebel LA; McCarthy SA; Chambers L; Shrikhande A; Wong S; Menniti FS; Schmidt CJ
Neuropharmacology; 2006 Aug; 51(2):386-96. PubMed ID: 16780899
[TBL] [Abstract][Full Text] [Related]
45. Phosphodiesterase 10A inhibitor activity in preclinical models of the positive, cognitive, and negative symptoms of schizophrenia.
Grauer SM; Pulito VL; Navarra RL; Kelly MP; Kelley C; Graf R; Langen B; Logue S; Brennan J; Jiang L; Charych E; Egerland U; Liu F; Marquis KL; Malamas M; Hage T; Comery TA; Brandon NJ
J Pharmacol Exp Ther; 2009 Nov; 331(2):574-90. PubMed ID: 19661377
[TBL] [Abstract][Full Text] [Related]
46. Design, synthesis and pharmacological evaluation of novel polycyclic heteroarene ethers as PDE10A inhibitors: Part I.
Das S; Harde RL; Shelke DE; Khairatkar-Joshi N; Bajpai M; Sapalya RS; Surve HV; Gudi GS; Pattem R; Behera DB; Jadhav SB; Thomas A
Bioorg Med Chem Lett; 2014 May; 24(9):2073-8. PubMed ID: 24725435
[TBL] [Abstract][Full Text] [Related]
47. The SAR development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10A inhibitors for the treatment of schizophrenia.
Ho GD; Michael Seganish W; Bercovici A; Tulshian D; Greenlee WJ; Van Rijn R; Hruza A; Xiao L; Rindgen D; Mullins D; Guzzi M; Zhang X; Bleickardt C; Hodgson R
Bioorg Med Chem Lett; 2012 Apr; 22(7):2585-9. PubMed ID: 22377514
[TBL] [Abstract][Full Text] [Related]
48. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of Tpl2 kinase and TNF-alpha production with 1,7-naphthyridine-3-carbonitriles: synthesis and structure-activity relationships.
Gavrin LK; Green N; Hu Y; Janz K; Kaila N; Li HQ; Tam SY; Thomason JR; Gopalsamy A; Ciszewski G; Cuozzo JW; Hall JP; Hsu S; Telliez JB; Lin LL
Bioorg Med Chem Lett; 2005 Dec; 15(23):5288-92. PubMed ID: 16165349
[TBL] [Abstract][Full Text] [Related]
50. Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches.
Halder AK; Amin SA; Jha T; Gayen S
SAR QSAR Environ Res; 2017 Mar; 28(3):253-273. PubMed ID: 28322591
[TBL] [Abstract][Full Text] [Related]
51. Discovery of novel potent imidazo[1,2-b]pyridazine PDE10a inhibitors.
Meegalla SK; Huang H; Illig CR; Parks DJ; Chen J; Lee YK; Wilson KJ; Patel SK; Cheung WS; Lu T; Kirchner T; Askari HB; Geisler J; Patch RJ; Gibbs AC; Rady B; Connelly M; Player MR
Bioorg Med Chem Lett; 2016 Sep; 26(17):4216-22. PubMed ID: 27491708
[TBL] [Abstract][Full Text] [Related]
52. Current landscape of phosphodiesterase 10A (PDE10A) inhibition.
Chappie TA; Helal CJ; Hou X
J Med Chem; 2012 Sep; 55(17):7299-331. PubMed ID: 22834877
[No Abstract] [Full Text] [Related]
53. Fragment-Based Discovery of Pyrimido[1,2-b]indazole PDE10A Inhibitors.
Chino A; Seo R; Amano Y; Namatame I; Hamaguchi W; Honbou K; Mihara T; Yamazaki M; Tomishima M; Masuda N
Chem Pharm Bull (Tokyo); 2018; 66(3):286-294. PubMed ID: 29491261
[TBL] [Abstract][Full Text] [Related]
54. Impact of N-Alkylamino Substituents on Serotonin Receptor (5-HTR) Affinity and Phosphodiesterase 10A (PDE10A) Inhibition of Isoindole-1,3-dione Derivatives.
Czopek A; Partyka A; Bucki A; Pawłowski M; Kołaczkowski M; Siwek A; Głuch-Lutwin M; Koczurkiewicz P; Pękala E; Jaromin A; Tyliszczak B; Wesołowska A; Zagórska A
Molecules; 2020 Aug; 25(17):. PubMed ID: 32854402
[TBL] [Abstract][Full Text] [Related]
55. Identification of phosphodiesterase-1 and 5 dual inhibitors by a ligand-based virtual screening optimized for lead evolution.
Yamazaki K; Kusunose N; Fujita K; Sato H; Asano S; Dan A; Kanaoka M
Bioorg Med Chem Lett; 2006 Mar; 16(5):1371-9. PubMed ID: 16337379
[TBL] [Abstract][Full Text] [Related]
56. Phosphodiesterase inhibitors as potential cognition enhancing agents.
Schmidt CJ
Curr Top Med Chem; 2010; 10(2):222-30. PubMed ID: 20166957
[TBL] [Abstract][Full Text] [Related]
57. Discovery of 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one (TAK-063), a highly potent, selective, and orally active phosphodiesterase 10A (PDE10A) inhibitor.
Kunitomo J; Yoshikawa M; Fushimi M; Kawada A; Quinn JF; Oki H; Kokubo H; Kondo M; Nakashima K; Kamiguchi N; Suzuki K; Kimura H; Taniguchi T
J Med Chem; 2014 Nov; 57(22):9627-43. PubMed ID: 25384088
[TBL] [Abstract][Full Text] [Related]
58. Quetiapine and novel PDE10A inhibitors potentiate the anti-BuChE activity of donepezil.
Sikora J; Podsiedlik M; Pietras T; Kosmalski M; Matłoka M; Moszczyński-Petkowski R; Wieczorek M; Markowicz-Piasecka M
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):1743-1750. PubMed ID: 32938236
[TBL] [Abstract][Full Text] [Related]
59. A comparative study of binding affinities for 6,7-dimethoxy-4-pyrrolidylquinazolines as phosphodiesterase 10A inhibitors using the linear interaction energy method.
Kjellgren ER; Glue OE; Reinholdt P; Meyer JE; Kongsted J; Poongavanam V
J Mol Graph Model; 2015 Sep; 61():44-52. PubMed ID: 26188794
[TBL] [Abstract][Full Text] [Related]
60. Medicinal chemistry strategies for the development of phosphodiesterase 10A (PDE10A) inhibitors - An update of recent progress.
Amin HS; Parikh PK; Ghate MD
Eur J Med Chem; 2021 Mar; 214():113155. PubMed ID: 33581555
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
